# Comprehensive Blood & Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/comprehensive-blood-and-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 100 |
| Citations | 227,877 |
| City | Bakersfield |
| Country | US |
| Description | Comprehensive Blood & Cancer Center is a research organisation in Bakersfield, US. OpenAlex records 1,019 works and 227,877 citations for it. 222 researchers list it as their most recent affiliation. |
| Homepage | http://www.cbccusa.com/ |
| OpenAlex ID | https://openalex.org/I4210133297 |
| Region | California |
| Researchers | 222 |
| ROR ID | https://ror.org/02vz7hv03 |
| Type | healthcare |
| Works | 1,019 |

## University papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer](https://scholariq.org/papers/vinorelbine-plus-cisplatin-vs-observation-in-resected-non-small-cell-lung-cancer/)
- [Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial](https://scholariq.org/papers/radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-iii/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC](https://scholariq.org/papers/liquid-biopsy-for-advanced-non-small-cell-lung-cancer-nsclc-a-statement-paper/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study](https://scholariq.org/papers/gefitinib-versus-placebo-in-completely-resected-non-small-cell-lung-cancer/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)

## University top topics

Showing 8 of 25.

- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.